291 related articles for article (PubMed ID: 7636731)
1. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
Kamei J; Ohsawa M; Saitoh A; Iwamoto Y; Suzuki T; Misawa M; Nagase H; Kasuya Y
J Pharmacol Exp Ther; 1995 Aug; 274(2):700-6. PubMed ID: 7636731
[TBL] [Abstract][Full Text] [Related]
2. Role of intracellular calcium in modification of mu and delta opioid receptor-mediated antinociception by diabetes in mice.
Ohsawa M; Nagase H; Kamei J
J Pharmacol Exp Ther; 1998 Aug; 286(2):780-7. PubMed ID: 9694934
[TBL] [Abstract][Full Text] [Related]
3. Behavioral effects of opioid peptides selective for mu or delta receptors. II. Locomotor activity in nondependent and morphine-dependent rats.
Locke KW; Holtzman SG
J Pharmacol Exp Ther; 1986 Sep; 238(3):997-1003. PubMed ID: 3018231
[TBL] [Abstract][Full Text] [Related]
4. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors.
Sánchez-Blázquez P; García-Espãna A; Garzón J
J Pharmacol Exp Ther; 1997 Mar; 280(3):1423-31. PubMed ID: 9067332
[TBL] [Abstract][Full Text] [Related]
7. Involvement of mu1-opioid receptor on oxycodone-induced antinociception in diabetic mice.
Nozaki C; Kamei J
Eur J Pharmacol; 2007 Apr; 560(2-3):160-2. PubMed ID: 17292346
[TBL] [Abstract][Full Text] [Related]
8. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
Capasso A; Sorrentino L
Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
[TBL] [Abstract][Full Text] [Related]
9. Effect of diabetes on the morphine-induced inhibition of gastrointestinal transit.
Kamei J; Ohsawa M; Misawa M; Nagase H; Kasuya Y
Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):165-9. PubMed ID: 7796321
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
[TBL] [Abstract][Full Text] [Related]
11. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
12. Involvement of supraspinal and peripheral naloxonazine-insensitive opioid receptor sites in the expression of μ-opioid receptor agonist-induced physical dependence.
Mori T; Komiya S; Uzawa N; Inoue K; Itoh T; Aoki S; Shibasaki M; Suzuki T
Eur J Pharmacol; 2013 Sep; 715(1-3):238-45. PubMed ID: 23707904
[TBL] [Abstract][Full Text] [Related]
13. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
14. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
15. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
[TBL] [Abstract][Full Text] [Related]
16. Precipitation of spinally mediated withdrawal signs by intrathecal administration of naloxone and the mu-receptor antagonist CTP in morphine-dependent mice.
Shook J; Kazmierski W; Hruby V; Burks T
NIDA Res Monogr; 1988; 81():143-8. PubMed ID: 2900467
[TBL] [Abstract][Full Text] [Related]
17. DAMGO stimulates the hypothalamo-pituitary-adrenal axis through a mu-2 opioid receptor.
Eisenberg RM
J Pharmacol Exp Ther; 1993 Aug; 266(2):985-91. PubMed ID: 8394926
[TBL] [Abstract][Full Text] [Related]
18. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
19. Morphine attenuates the expression of sensitization to ethanol, but opioid antagonists do not.
Abrahao KP; Quadros IM; Souza-Formigoni ML
Neuroscience; 2008 Oct; 156(4):857-64. PubMed ID: 18804151
[TBL] [Abstract][Full Text] [Related]
20. Involvement of delta 2 opioid receptors in the development of morphine dependence in mice.
Miyamoto Y; Portoghese PS; Takemori AE
J Pharmacol Exp Ther; 1993 Mar; 264(3):1141-5. PubMed ID: 8383738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
